Bladder Cancer

>

Latest News

"These findings are particularly significant for Japanese patients, as our treatment options have been more limited compared to other regions," according to Keiji Inoue, MD, PhD, a professor in the Department of Urology at Kochi Medical School.
Nadofaragene Firadenovec Yields Responses in BCG-Unresponsive NMIBC

April 22nd 2025

Data from a Japanese trial add to the body of evidence supporting the favorable efficacy and safety of nadofaragene firadenovec for this NMIBC population.

In quarter 1 of 2025, nogapendekin alfa inbakicept received regenerative medicine advanced therapy designation for lymphopenia.
sBLAs Submitted for Nogapendekin Alfa Inbakicept in Lymphopenia/NMIBC

April 16th 2025

Combining durvalumab with chemotherapy produced a good safety profile without increasing surgical risk in the phase 2 iNDUCT-GETUG V08 trial.
Durvalumab Combo Shows Encouraging Preliminary Data in High-Risk UTUC

April 8th 2025

FDA Approves Adjuvant Durvalumab/Chemo in Muscle-Invasive Bladder Cancer
FDA Approves Adjuvant Durvalumab/Chemo in Muscle-Invasive Bladder Cancer

March 28th 2025

No grade 3 or higher treatment-related adverse effects or deaths were reported among those with non-muscle invasive bladder cancer in the BOND-003 trial.
Cretostimogene Grenadenorepvec Yields Sustained Antitumor Activity in NMIBC

March 25th 2025

Video Series
Video Interviews
Podcasts
Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

More News